These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 8468276

  • 1. Treatment of therapy-related acute myelogenous leukemia and myelodysplastic syndromes.
    Ballen KK, Antin JH.
    Hematol Oncol Clin North Am; 1993 Apr; 7(2):477-93. PubMed ID: 8468276
    [Abstract] [Full Text] [Related]

  • 2. Treatment of acute myelogenous leukemia and myelodysplastic syndromes.
    Estey EH.
    Semin Hematol; 1995 Apr; 32(2):132-51. PubMed ID: 7652581
    [No Abstract] [Full Text] [Related]

  • 3. Toxicity and outcome of children with treatment related acute myeloid leukemia.
    Tabori U, Revach G, Nathan PC, Strahm B, Rachlis A, Shago M, Grant R, Doyle J, Malkin D.
    Pediatr Blood Cancer; 2008 Jan; 50(1):17-23. PubMed ID: 17252569
    [Abstract] [Full Text] [Related]

  • 4. Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.
    Au WY, Chan LC, Liang R, Kwong YL.
    Am J Hematol; 2006 Jun; 81(6):471-3. PubMed ID: 16680740
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
    Kröger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D, Sierra J, Zander A, Niederwieser D, de Witte T, Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
    Bone Marrow Transplant; 2006 Jan; 37(2):183-9. PubMed ID: 16299545
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Treatment of therapy-related leukemia and myelodysplastic syndrome.
    Kantarjian HM, Estey EH, Keating MJ.
    Hematol Oncol Clin North Am; 1993 Feb; 7(1):81-107. PubMed ID: 7680643
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A.
    Pathobiology; 2007 Feb; 74(2):97-114. PubMed ID: 17587881
    [Abstract] [Full Text] [Related]

  • 13. Special clinical concerns/problems in the management of MDS and secondary acute myeloid leukemias.
    Venugopal P, Manson S, Preisler HD.
    Cancer Treat Res; 2001 Feb; 108():257-65. PubMed ID: 11702603
    [No Abstract] [Full Text] [Related]

  • 14. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Leukaemia cutis in a patient treated for breast cancer.
    Weinel S, Malone J, Jain D, Callen JP.
    Australas J Dermatol; 2009 Feb; 50(1):52-5. PubMed ID: 19178494
    [Abstract] [Full Text] [Related]

  • 18. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ.
    J Clin Oncol; 2005 Aug 20; 23(24):5675-87. PubMed ID: 16110027
    [Abstract] [Full Text] [Related]

  • 19. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
    Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka D.
    Am J Hematol; 2001 Aug 20; 67(4):227-33. PubMed ID: 11443634
    [Abstract] [Full Text] [Related]

  • 20. High incidence of therapy-related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders.
    Bowcock SJ, Rassam SM, Lim Z, Ward SM, Ryali MM, Mufti GJ.
    Br J Haematol; 2006 Jul 20; 134(2):242-3. PubMed ID: 16846486
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.